Trial Profile
Randomized phase III trial of standard immunotherapy (IO) by checkpoint inhibitors, versus reduced dose intensity of IO in patients with metastatic cancer in response after 6 months of standard IO
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Dec 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Avelumab (Primary) ; Bevacizumab (Primary) ; Cabozantinib (Primary) ; Durvalumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary)
- Indications Bladder cancer; Brain metastases; Head and neck cancer; Liver cancer; Lung cancer; Malignant melanoma; Merkel cell carcinoma; Renal cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms MOIO
- 08 Dec 2023 New trial record